Management of Epilepsy in Adults: Treatment Guidelines

Louis F. Trost IIIDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, MD,

Richard C. WenderDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, MD,

Cary C. SuterDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, MD,

Jay H. RosenbergDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, MD,

Diana I. BrixnerDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, PhD, RPh,

Ann Marie Von WorleyDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, RN,

Margaret J. GunterDr Wender is on the advisory board of Enterix, GlaxoSmithKline, and Gl View. Dr Rosenberg is on the speakers’ bureau for Teva, Cephalon, Serono, and Berlex. Dr Brixner has received research support from Novartis. Dr Trost, Dr Suter, Ms Von Worley, and Dr Gunter disclose no financial Interests in this article. Partial funding for guideline development was obtained from Novartis and the CDC National Center for Chronic Disease Prevention and Health Promotion.

, PhD & National Epilepsy Management Panel show all

PREVIEW

In this second of two articles on new epilepsy guidelines for primary care physicians, the authors discuss which treatments are the most effective in adults with this disease. They describe the antiepileptic drugs that are currently approved and elucidate the differences between established and newer options. Detailed algorithms cover pharmacotherapy, follow-up, and ongoing maintenance.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Management of Epilepsy in Adults: Treatment Guidelines

Information for

Open access

Opportunities

Help and information

Management of Epilepsy in Adults: Treatment Guidelines

PREVIEW

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature